EPimedokoreanin B shows scavenge the DPPH radical activity, it can inhibit the proliferation of MCF-7 and HepG2 in dose-dependant manner. EPimedokoreanin B can significantly inhibit the formation of both N (?μ) -(carboxymethyl)lysine (CML) and N (??) -(carboxymethyl)arginine (CMA), it may prevent clinical compliCATions of diabetes by inhibiting advanced glyCATion end-products (AGEs).

Epimedokoreanin B shows scavenge the DPPH radical activity, it can inhibit the proliferation of MCF-7 and HepG2 in dose-dependant manner. Epimedokoreanin B can significantly inhibit the formation of both N (Iμ) -(carboxymethyl)lysine (CML) and N (I?) -(carboxymethyl)arginine (CMA), it may prevent clinical complications of diabetes by inhibiting advanced glycation end-products (AGEs).

161068-53-7

C25H26O6

422.47

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years